SOUTH SAN FRANCISCO, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ: CTMX ), a leader in the field of conditionally activated therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company''s Investigational New Drug (IND) application for CX-904, an EGFRxCD3 T-cell-engaging bispecific antibody being co-developed by CytomX and Amgen. "The impressive innovation of CX-904''s design and its advancement into the clinical setting underscores our commitment to destroying cancer differently. The CX-904 IND also marks the sixth therapeutic candidate and the third treatment modality overall to enter the clinic from our versatile and tunable Probody platform, reinforcing our leadership in the field of conditional activation of biologic therapeutics," said Sean McCarthy, D.Phil., president, chief executive officer and chairman of CytomX Therapeutics. "Our masked Probody T-cell engagers are designed to harness the power of this highly potent modality.

CytomX Therapeutics Inc Shares Near 52-Week Low - Market Mover

02:49am, Friday, 14'th Jan 2022 Kwhen Finance
CytomX Therapeutics Inc (CTMX) shares closed today at 1.6% above its 52 week low of $3.68, giving the company a market cap of $245M. The stock is currently down 13.2% year-to-date, down 50.8% over the past 12 months, and down 67.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 66.6% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 335.3% The company's stock price performance over the past 12 months lags the peer average by 66.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that Sean McCar
CytomX Therapeutics, Inc. (NASDAQ:CTMX) with the stream of -40.00% also noticed, India Skillz Inc. (NYSE:SKLZ) encountered a rapid change of 10.28% in the last hour of Tuesdays trading session. CytomX The post Hot Stock in the Spotlight: CytomX Therapeutics, Inc. (NASDAQ:CTMX), Skillz Inc. (NYSE:SKLZ) appeared first on Stocks Equity .
CytomX Therapeutics Inc. (NASDAQ:CTMX) traded at $3.90 at last check on Tuesday, December 21, made a downward move of -39.49% on its previous days price. Looking at the stock we see that its previous close was $6.45 and the beta (5Y monthly) reads 0.68 with the days price range being $5.89 $6.51. In terms Before You Invest, Make Sure You Check This CytomX Therapeutics Inc. (NASDAQ: CTMX) Analysis Read More »

Why CytomX Therapeutics Stock Is Crashing Today

05:12pm, Tuesday, 21'st Dec 2021 The Motley Fool
Investors didn't like the company's preliminary phase 2 results for its experimental cancer therapy.
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients Show Lackluster Efficacy CytomX

Why CytomX Therapeutics Stock Is Crashing Today

12:12pm, Tuesday, 21'st Dec 2021
Investors didn't like the company's preliminary phase 2 results for its experimental cancer therapy.
CytomX Therapeutics Inc (NASDAQ: CTMX) announced preliminary Phase 2 results of CX-2029 in patients with either advanced squamous non-small cell lung cancer (sqNSCLC) or head and neck squamous cell
-Objective response rate of 18.8 percent and disease control rate of 87.5 percent in unselected advanced squamous non-small cell lung cancer. Enrollment continues-

CytomX: Pullbacks Are Opportunities

05:17pm, Tuesday, 14'th Dec 2021
CTMX went up 50% since my September coverage but is down to 25% now. They had exciting news about a patent dispute and will present two key misstated datasets in the next 2-3 months.
Virginia Retirement Systems ET AL boosted its holdings in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 27.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 150,300 shares of the biotechnology companys stock after buying an additional 32,600 shares during []
Equities research analysts expect CytomX Therapeutics, Inc. (NASDAQ:CTMX) to report ($0.19) earnings per share (EPS) for the current quarter, Zacks reports. Five analysts have provided estimates for CytomX Therapeutics earnings. The lowest EPS estimate is ($0.34) and the highest is $0.29. CytomX Therapeutics reported earnings of ($0.31) per share during the same quarter last year, []
CytomX Therapeutics, Inc. (NASDAQ:CTMX) has been assigned an average rating of Buy from the seven ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The average twelve-month price []
CytomX Therapeutics Inc. (NASDAQ:CTMX) concluded the trading at $6.61 on Friday, December 03 with a fall of -4.20% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $6.90 and 5Y monthly beta was reading 0.70 with its price kept floating in the CytomX Therapeutics Inc. (CTMX) Recovers 54.44% From Low: Are We There Yet? Read More »
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE